Estradiol hemisuccinate
| Clinical data | |
|---|---|
| Trade names | Eutocol, Hosterona (with progesterone) |
| Other names | Estradiol succinate; Estradiol 17β-hemisuccinate; Estradiol 17β-succinate |
| Routes of administration | By mouth, intramuscular injection |
| Drug class | Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.163.857 |
| Chemical and physical data | |
| Formula | C22H28O5 |
| Molar mass | 372.461 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Estradiol hemisuccinate (brand name Eutocol), or simply estradiol succinate, also known as estradiol 17β-hemisuccinate, is an estrogen medication and an estrogen ester – specifically, the hemisuccinate ester of estradiol. It is used as a component of hormone replacement therapy for menopause. Like other estrogens, estradiol hemisuccinate has been found to have beneficial effects on the skin, with improvement of skin thickness observed.
Estradiol hemisuccinate is also a component of estradiol hemisuccinate/progesterone (brand name Hosterona), an injectable preparation used to induce withdrawal bleeding in women with amenorrhea.